Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note published on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $22.00 price objective on the stock.

STOK has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners started coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Chardan Capital started coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Up 0.4 %

Shares of NASDAQ:STOK opened at $9.00 on Wednesday. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58. The firm’s 50 day moving average price is $11.91 and its 200 day moving average price is $13.04. The stock has a market cap of $476.70 million, a price-to-earnings ratio of -4.29 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts anticipate that Stoke Therapeutics will post -2.03 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the sale, the insider now directly owns 51,277 shares of the company’s stock, valued at $618,913.39. This represents a 16.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Stoke Therapeutics in the second quarter valued at about $29,000. Intech Investment Management LLC acquired a new stake in Stoke Therapeutics in the third quarter valued at about $160,000. The Manufacturers Life Insurance Company boosted its holdings in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares in the last quarter. Profund Advisors LLC acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $201,000. Finally, Mesirow Financial Investment Management Inc. purchased a new position in shares of Stoke Therapeutics during the 3rd quarter worth approximately $192,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.